| Acquired resistance to immune checkpoint inhibitors AJ Schoenfeld, MD Hellmann Cancer cell 37 (4), 443-455, 2020 | 683 | 2020 |
| Severe immune-related adverse events are common with sequential PD-(L) 1 blockade and osimertinib AJ Schoenfeld, KC Arbour, H Rizvi, AN Iqbal, SM Gadgeel, J Girshman, ... Annals of Oncology 30 (5), 839-844, 2019 | 370 | 2019 |
| Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer AJ Schoenfeld, JM Chan, D Kubota, H Sato, H Rizvi, Y Daneshbod, ... Clinical Cancer Research 26 (11), 2654-2663, 2020 | 322 | 2020 |
| COVID-19 in patients with lung cancer J Luo, H Rizvi, IR Preeshagul, JV Egger, D Hoyos, C Bandlamudi, ... Annals of Oncology 31 (10), 1386-1396, 2020 | 319 | 2020 |
| Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas AJ Schoenfeld, H Rizvi, C Bandlamudi, JL Sauter, WD Travis, ... Annals of Oncology 31 (5), 599-608, 2020 | 277 | 2020 |
| Adverse effects associated with proton pump inhibitors AJ Schoenfeld, D Grady JAMA internal medicine 176 (2), 172-174, 2016 | 252 | 2016 |
| SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas N Rekhtman, J Montecalvo, JC Chang, D Alex, RN Ptashkin, N Ai, ... Journal of Thoracic Oncology 15 (2), 231-247, 2020 | 250 | 2020 |
| Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non–small-cell lung cancer in CheckMate 227 JR Brahmer, JS Lee, TE Ciuleanu, R Bernabe Caro, M Nishio, L Urban, ... Journal of Clinical Oncology 41 (6), 1200-1212, 2023 | 238 | 2023 |
| ROS1-dependent cancers—biology, diagnostics and therapeutics A Drilon, C Jenkins, S Iyer, A Schoenfeld, C Keddy, MA Davare Nature reviews Clinical oncology 18 (1), 35-55, 2021 | 226 | 2021 |
| The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer AJ Schoenfeld, C Bandlamudi, JA Lavery, J Montecalvo, A Namakydoust, ... Clinical Cancer Research 26 (21), 5701-5708, 2020 | 207 | 2020 |
| The superiority of conservative resection and adjuvant radiation for craniopharyngiomas A Schoenfeld, M Pekmezci, MJ Barnes, T Tihan, N Gupta, KR Lamborn, ... Journal of neuro-oncology 108, 133-139, 2012 | 187 | 2012 |
| Non-viral precision T cell receptor replacement for personalized cell therapy SP Foy, K Jacoby, DA Bota, T Hunter, Z Pan, E Stawiski, Y Ma, W Lu, ... Nature 615 (7953), 687-696, 2023 | 182 | 2023 |
| Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1/2 single-group open-label trial AY Helena, AJ Schoenfeld, A Makhnin, R Kim, H Rizvi, D Tsui, C Falcon, ... JAMA oncology 6 (7), 1048-1054, 2020 | 129 | 2020 |
| Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer JJ Lin, NJ Choudhury, S Yoda, VW Zhu, TW Johnson, R Sakhtemani, ... Clinical Cancer Research 27 (10), 2899-2909, 2021 | 105 | 2021 |
| Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front–mutant ROS1-rearranged non–small cell lung cancer MR Yun, DH Kim, SY Kim, HS Joo, YW Lee, HM Choi, CW Park, SG Heo, ... Clinical Cancer Research 26 (13), 3287-3295, 2020 | 99 | 2020 |
| Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers M Vojnic, D Kubota, C Kurzatkowski, M Offin, K Suzawa, R Benayed, ... Journal of Thoracic Oncology 14 (5), 802-815, 2019 | 92 | 2019 |
| Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors AH Nassar, E Adib, S Abou Alaiwi, T El Zarif, S Groha, EW Akl, PV Nuzzo, ... Cancer Cell 40 (10), 1161-1172. e5, 2022 | 82 | 2022 |
| Variation in quality of urgent health care provided during commercial virtual visits AJ Schoenfeld, JM Davies, BJ Marafino, M Dean, C DeJong, NS Bardach, ... JAMA internal medicine 176 (5), 635-642, 2016 | 82 | 2016 |
| Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung CP Concepcion, S Ma, LM LaFave, A Bhutkar, M Liu, LP DeAngelo, ... Cancer discovery 12 (2), 562-585, 2022 | 79 | 2022 |
| Brigatinib in patients with alectinib-refractory ALK-positive NSCLC JJ Lin, VW Zhu, AJ Schoenfeld, BY Yeap, A Saxena, LA Ferris, ... Journal of Thoracic Oncology 13 (10), 1530-1538, 2018 | 77 | 2018 |
Gregory J. Riely, MD, PhDMemorial Sloan Kettering Cancer CenterVerified email at MSKCC.org
